Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2018

View Archived Issues

CB-4211 potentiates insulin effects on fatty acid metabolism and glucose homeostasis

CYP11B1 enzyme, a potential predictive biomarker for healing failure in diabetic foot ulcers

Serum netrin-1, a potential early biomarker for impaired fasting glucose and type 2 diabetes

NOVA2 or DDX6 mutations alter RNA metabolism leading to intellectual disability

[89]Zr-DFO-dinutuximab as novel radiotracer for selective detection of GD2-positive tumors

MR-438 peptidomimetic presented as a new radiosensitizing agent in medulloblastoma

Topline results announced from phase I study of ZYN-001 THC-prodrug patch

Expanded indication for Sprycel approved in Europe to include treatment of children with CP-CML

Safety review committee recommends continuation of phase Ib/II SENSITIZE study

Phase IIb study of LL-37 receives approval in Sweden

Vertex Pharmaceuticals presents new azoles for demyelinating diseases

Detection of NDMA in Zhejiang Huahai's valsartan leads to EMA review and product recall

Boehringer Ingelheim divulges SLC13A5 inhibitors

EMA validates Clovis' application for Rubraca as maintenance treatment for recurrent ovarian cancer

Icahn School of Medicine at Mount Sinai discloses PROTAc compounds for cancer

Nanjing TransThera Biosciences synthesizes protein kinase inhibitors for cancer

Zydus Cadila and CSIR-IMTECH collaborate to tackle drug-resistant infections

Medshine Discovery and collaborator patent CCR-2 and CCR-5 antagonists

Herantis initiates development program for noninvasive CDNF

Topline results from final analysis of phase II trial of BAN-2401 in Alzheimer's

MHRA approves Xonvea in U.K. for nausea and vomiting of pregnancy

Regulus Therapeutics announces corporate restructuring

Enzyvant partners with Visikol on digital pathology assay to support RVT-802

Takeda advances acquisition of TiGenix

Introducing BioWorld Science: supporting R&D decisions through drug discovery and preclinical news

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...